Mar. 27 at 3:30 PM
Citizens on
$IMMX said in a note tt investors—We reiterate our Market Outperform rating and price target of
$23 on Immix Biopharma based on a revenue and earnings multiples analysis.
$JNJ -
$LEGN BMY - TSVT GILD - ACLX AZN ABBV
Citizens added—Recently, Immix reported 4Q25 earnings, and based on our conversation with management, we remain confident on the cadence of milestones over the next 6-12 months.
With NXC-201 on track to report final results and file a BLA in 2H26 a potential commercial launch by mid-2027, and a solid cash position of
$100.4MM, we believe Immix shares represent an attractive investment opportunity,
with ~42% potential downside (bear case
$5) and ~409% potential upside (bull case
$44).
